A stock image of a health care professional holding a syringe.Photo:Getty
Getty
A promising new trial found that anOzempic-like drug used to treat diabetes might also help patients withParkinson’s disease.
Lixisenatide — a glucagon-like peptide-1 receptor agonist like Ozempic and Wegovy — previously showed neuroprotective properties in a mouse model of the degenerative brain condition, according tothe resultsof the phase-two, placebo-controlled human trial, published on April 3 inThe New England Journal of Medicine.
The trial followed 156 people — between the ages of 40 and 75 — with early Parkinson’s disease, all of whom continued to take their usual Parkinson’s medication.
One group was administered an additional daily injection of lixisenatide for 12 months, while the other group received a placebo.
A stock image of an injectable medication.Getty
The placebo group experienced worsened motor symptoms, while the patients taking lixisenatide showed no progression of their motor disability, though some had gastrointestinal side effects such as nausea and vomiting, which are common across all GLP-1 medications.
The difference between the two groups remained two months after the trial’s end and patients stopped taking Sanofi’s drug.
Never miss a story — sign up forPEOPLE’s free daily newsletterto stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories.
While the results are encouraging, the researchers said in their published report that “longer and larger trials are needed to determine the effects and safety of lixisenatide” in people with Parkinson’s disease, as well as how long the benefits of the drug last.
“Whether the apparent effect of lixisenatide on motor disability persists with longer exposure and at other stages of Parkinson’s disease remains to be determined,” the researchers noted.
Sanofi pulled lixisenatide, sold under the brand name Adlyxin, from the U.S. market in January 2023. The French pharmaceutical and health care companysaid at the timethat the discontinuation “was a business decision and was not due to safety or efficacy issues.”
In a statement toCNBC, Sanofi — which was not involved in the new phase-two trial — said it was “pleased to see the positive outcomes” of the study and is open to “a discussion with the investigators of the study on providing support for their next phase of research.”
source: people.com
